M
Mohammed Ahmed Rashid
Researcher at University College London
Publications - 56
Citations - 646
Mohammed Ahmed Rashid is an academic researcher from University College London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 9, co-authored 37 publications receiving 537 citations. Previous affiliations of Mohammed Ahmed Rashid include Royal Free Hospital & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors
Mohid S. Khan,Theodora Tsigani,Mohammed Ahmed Rashid,Jeremy S. Rabouhans,Dominic Yu,Tu Vinh Luong,Martyn Caplin,Tim Meyer +7 more
TL;DR: This is the first systematic analysis showing EpCAM expression and CTC detection in NETs and seems to be associated with progressive disease and may provide useful prognostic information given the variable survival rates in these tumors.
Journal ArticleDOI
Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer
Marco Loddo,Sarah R. Kingsbury,Mohammed Ahmed Rashid,Ian Proctor,C Holt,J Young,S El-Sheikh,Mary Falzon,K L Eward,T. C. Prevost,T. C. Prevost,Richard Sainsbury,Kai Stoeber,Gareth H. Williams +13 more
TL;DR: The authors' biomarker algorithm provides novel insights into the cell-cycle state of dynamic tumour cell populations in vivo, of major prognostic significance and may impact on individualised therapeutic decisions.
Journal ArticleDOI
Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma
Anjana A. Kulkarni,Sarah R. Kingsbury,Slavica Tudzarova,Hye-Kyung Hong,Marco Loddo,Mohammed Ahmed Rashid,Sara Rodriguez-Acebes,A T Prevost,Jonathan A. Ledermann,Kai Stoeber,Gareth H. Williams +10 more
TL;DR: Findings show that Cdc7 kinase predicts survival and is a potent anticancer target in epithelial ovarian carcinoma, highlighting its potential as a predictor of susceptibility to small molecule kinase inhibitors currently in development.
Journal ArticleDOI
Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging
Robert Goldstein,Jane K. Sosabowski,Maria Livanos,Julius Leyton,Kim Vigor,Gaurav Bhavsar,Gabriela Nagy-Davidescu,Mohammed Ahmed Rashid,Enrique Miranda,Jenny Yeung,Berend Tolner,Andreas Plückthun,Stephen J. Mather,Tim Meyer,Kerry A. Chester +14 more
TL;DR: Radiolabelled DARPin (HE)3-G3 is a versatile radioligand with potential to allow the acquisition of whole-body HER2 scans on the day of administration and demonstrated that radioactivity from 111In-(HE) 3-G 3 was better maintained in tumours and cleared faster from serum thanRadioactivity from 125I-(HE), achieving superior tumour-to-blood ratios.
Journal ArticleDOI
Targeting DNA Replication before it Starts: Cdc7 as a Therapeutic Target in p53-Mutant Breast Cancers
Sara Rodriguez-Acebes,Ian Proctor,Marco Loddo,A Wollenschlaeger,Mohammed Ahmed Rashid,Mary Falzon,A Toby Prevost,A Toby Prevost,Richard Sainsbury,Kai Stoeber,Gareth H. Williams +10 more
TL;DR: In this article, the cell-cycle protein Cdc7 regulates S phase by promoting DNA replication, which is an attractive therapeutic target for triple-receptor negative and Her2-overexpressing breast cancer.